Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation.

Abstract

Severe tricuspid regurgitation remains a challenging heart-valve disease to effectively treat with high morbidity and mortality at mid-term. Currently guideline-directed medical treatment is limited to escalating dose of diuretics, and the rationale and timing of open-heart surgery remains controversial. Emerging percutaneous therapies for severe tricuspid regurgitation continue to show promising results in early feasibility studies. However, randomized trial data is lacking. Additionally, many patients are deemed unsuitable for these emerging therapies due to anatomical or imaging constraints. Given the technical simplicity of the bicaval valve implantation (CAVI) technique compared to other transcatheter devices, CAVI is postulated as a suitable alternative for a wide variety of patients affected with severe+ tricuspid regurgitation. In this review we illustrate the current evidence and ongoing uncertainties of CAVI, focusing on the novel CAVI-specific devices.

• Authors: Omar Abdul-Jawad Altisent, Rimantas Benetis, Egle Rumbinaite, Vaida Mizarien, Pau Codina, Francisco Gual-Capllonch, Giosafat Spitaleri, Eduard Fernandez-Nofrerias, Antoni Bayes-Genis, Rishi Puri
• Journal: Journal of clinical medicine (J Clin Med) Vol. 10 Issue 19 (Oct 07 2021) ISSN: 2077-0383 [Print] Switzerland
• PMID: 34640619 (Publication Type: Journal Article, Review)